1Leslie WD, Bernstein CN, Leboff MS. AGA techincal review on osteoporosis in hepatic disorders. Gastroenterology, 2003, 125:941-966.
2Ormarsdottir S, Ljunggren O, MaUmin H, et al. Low body mass index and use of eortieosteroids, but not cholestasis, are risk factors for osteoporosis in patients with chronic liver disease. J Hepatol, 1999,31:84-90.
3Sokhi RP, Anantharaju A, Kondaveeti R, et al. Bone mineral density among cirrhotic patients awaiting liver transplantation. Liver Transpl,2004,10:648-653.
4Menon KV, Angulo P, Weston S, et al. Bone disease in primary biliary cirrhosis: independent indicators and rate of progression. J Hepatol, 2001, 35:316-323.
5Crawford BA, Kam C, Donaghy AJ, et al. The heterogeneity of bone disease in cirrhosis: a multivariaet analysis. Osteoporos Int,2003. 14:987-994.
6Galolego-Rojo, FJ, Gonmlez-Calvin JL, Munoz-Tortes M, et al. Bone mineral density, serum insulin-like growth factor 1, and bone turnover markers in viral cirrhosis. Hepatology, 1998, 28:695-699.
7Collier JD, Ninkovic M, Compston JE. Guidelines on the management of osteoporosis associated with chomic liver disease. Gut, 2002,50(Suppl 1): i1-i9.
8Shiomi S, Masaki K, Habu D, et al. Caleitriol for bone disease in patients with cirrhosis of the liver. J Gastroenterol Hepatol, 1999,14:547-552.
9Olsson R, Mattsson LA, Obrant K, et al. Estrogen-progestogen therapy for low bone mineral density in primary biliary cirrhosis. Liver, 1999, 19:188-192.
10Isoniemi H, Appelberg J, Nilsson CG, et al. Transdermal oestrogen therapy protects postmenopausal liver transplant women from osteoporosis. A2-yearfollow-up study. J Hepatol, 2001,34:299-305.
